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The nature of the relationship between cannabis use (CU) and psychosis is complex and
remains unclear. Researchers and clinicians remain divided regarding key issues such as
whether or not cannabis is an independent cause of psychosis and schizophrenia.This paper
reviews the field in detail, examining questions of causality, the neurobiological basis for
such causality and for differential inter-individual risk, the clinical and cognitive features of
psychosis in cannabis users, and patterns of course and outcome of psychosis in the con-
text of CU.The author proposes two major pathways from cannabis to psychosis based on
a differentiation between early-initiated lifelong CU and a scenario where vulnerable indi-
viduals without a lifelong pattern of use consume cannabis over a relatively brief period of
time just prior to psychosis onset. Additional key factors determining the clinical and neu-
robiological manifestation of psychosis as well as course and outcome in cannabis users
include: underlying genetic and developmental vulnerability to schizophrenia-spectrum dis-
orders; and whether or not CU ceases or continues after the onset of psychosis. Finally,
methodological guidelines are presented for future research aimed at both elucidating the
pathways that lead from cannabis to psychosis and clarifying the long-term outcome of the
disorder in those who have a history of using cannabis.
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INTRODUCTION AND HISTORICAL PERSPECTIVE
Cannabis sativa is the most widely used drug in the world and
archeological evidence from China indicates that humans used
cannabis as early as 4000 BCE (1). An association between CU
and mental illness, in particular psychotic illness, was recog-
nized as early as 1895 in a report by the Indian Hemp Drugs
Commission (2).
It is worth noting several extracts from this report, as they
suggest that clinicians working more than a century ago, were
similarly uncertain regarding the nature of the observed associa-
tion between cannabis and psychosis. Curiously, it appears from
these extracts that our clinical forbearers were indeed conscious
of several fundamental issues which modern science is only now
confirming in relation to the effects of cannabis on the human
brain. In the twelfth chapter, the report (2) states:
In relation to a causal relationship. . .
In answering the question, therefore, on what the evidence
rests that hemp drugs may induce mental aberration, the
Commission would offer the following remarks: The evi-
dence may be considered under two heads – (a) popular;
(b) scientific. The popular idea that the use of hemp drugs
may induce insanity can be traced back for many centuries,
and the present day views on the subject are no doubt the
outcome of old popular ideas which have been handed down
and become concrete.
But. . . we have a number of instances where the hemp
drug habit has been so established in relation to the insanity
that, admitting (as we must admit) that hemp drugs as intox-
icants cause more or less of cerebral stimulation, it may be
accepted as reasonably proved, in the absence of evidence of
other cause, that hemp drugs do cause insanity.
In relation to underlying biological processes. . .
The acute symptoms correspond to the temporary satura-
tion of the body with the poison, while the chronic symp-
toms are the expression of definite anatomical lesions in the
brain gradually developed under toxic influence. . . Further,
in regard to what has been said about hemp drug mania, it
may be noted that it is not improbable, though it has not been
established by evidence, that prolonged abuse of the drugs
may give rise in some cases to definite brain lesions result-
ing in a progressive weakening of all the faculties leading to
dementia.
In relation to differential vulnerability to psychosis. . .
In respect to the alleged mental effects of the drugs. It may
indeed be accepted that in the case of specially marked neu-
rotic diathesis, even the moderate use may produce mental
injury. . . The individual factor with its idiosyncrasies plays
here, as everywhere, a very important part. . . Nervous and
predisposed persons appear to be more easily affected than
normal subjects.
In relation to specificity of symptoms of psychosis in cannabis
users. . .
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The evidence obtained by the Commission appears to indi-
cate that in the cases of alleged hemp drug insanity which find
their way into asylums, there are no typical features in the
premonitory symptoms and no pathognomonic symptoms
in the insane condition on which to base a determination
of causation. . . The majority of medical witnesses who have
studied the subject are clearly of opinion that there is nothing
typical in the symptomatology of hemp drug mania to dis-
tinguish it from mania due to other causes. But at the same
time several express an opinion that the symptoms are of
shorter duration in hemp drug mania than in mania due to
other causes. . . The careful inquiry which has been made by
the Commission into all the alleged hemp drugs cases admit-
ted in one year into asylums in British India demonstrates
conclusively that the usual mode of differentiating between
hemp drug insanity and ordinary mania was in the highest
degree uncertain, and therefore fallacious.
Interestingly, it seems that clinicians in British India encoun-
tered the same difficulties in establishing cannabis as the causal
agent in cases of cannabis-using individuals presenting with psy-
chotic illness. In fact, as occurs too often in contemporary clinical
practice, this difficulty also led clinicians in that era to resort to
over-diagnosis of cannabis-induced psychosis, as is evident in the
following extract:
Surgeon-Major Willcocks, of Agra, says: “Ordinarily it has
been the practice to enter hemp drugs as the cause of insanity
where it has been shown that the patient used these drugs.
I cannot say precisely why this is the practice. It has come
down as the traditional practice.”
Reference to this historical enquiry into the relationship between
cannabis and psychosis, highlights a number of key issues that lie
at the center of modern research in this field. In reviewing the rela-
tionship between cannabis and psychosis, there are six questions
that need to be addressed:
1. Is cannabis an independent cause of psychosis?
2. If so, what are the neurobiological processes underlying this
causal relationship?
3. Is the risk for psychosis the same in all individuals using
cannabis; and if not, is there a neurobiological explanation for
differential risk?
4. Are there specific clinical features of psychosis in cannabis users
that differentiates them from psychosis in non-cannabis users?
5. What are the cognitive effects of cannabis use in individuals
with psychosis?
6. Does cannabis use impact on course and outcome in individu-
als with psychosis?
In this review, each of these questions will be addressed and
the relevant accumulated evidence presented. In conclusion, I
will consider the issue of whether there might be different path-
ways from cannabis use (CU) to psychotic illness; and present an
evidence-based hypothesis that will hopefully offer some direction
for future research in this field.
CANNABIS AND RISK FOR PSYCHOSIS – A CAUSAL
RELATIONSHIP?
In examining the evidence for a causal relationship between
cannabis and psychosis, it is important to acknowledge a num-
ber of limitations that are inherent in this research field. The first
is the matter of definitions. Published studies vary in terms of the
population upon which they focus – some studies limit their inclu-
sion criteria to a narrow definition of schizophrenia, while others
include a broad definition of psychotic disorders. Similarly, there
is marked variability between studies in terms of defining “CU”
(3). CU may be defined as current use or recent use or lifetime
use; and within these categories there are further differences in
definition. For example, recent use may be regarded as: use within
the last month; daily use for at least the last month; weekly use for
at least the last month; or as varying frequencies of use over the last
3 months or even 6 months. Other limitations include: most stud-
ies measure CU based on self-report, which tends to be associated
with under-reporting; self-report of CU is subject to recall bias; in
most cases, there is limited information on other substance use,
so that analyses are often unable to control for the confounding
effects of other substances such as stimulants; it is often difficult to
control for factors such as potency of cannabis, frequency of use,
and amount of cannabis consumed, due to statistical power issues;
and finally and perhaps most importantly, most studies are unable
to demonstrate temporal priority of cannabis in relation to early
prodromal features of psychosis [the Dunedin study is one of the
few that have achieved this methodologically (4, 5)].
These limitations are highly relevant in attempting to estab-
lish a causal relationship between “CU” and “psychosis.” This is
because any attempt to establish“causation”must fulfill the follow-
ing criteria as defined by Susser (6): association; temporal priority;
and direction (where the last implies that changes in the putative
cause will actually lead to changes in the outcome, and that the
association between putative cause and outcome does not derive
from a third factor common to both) (5). Other criteria for cau-
sation listed by Hill (7) include: strength (i.e., a dose-response
relationship); consistency; specificity; biological gradient; tem-
porality; coherence; and plausibility (i.e., a plausible biological
mechanism linking exposure and outcome). Thus the evidence-
base on cannabis and psychosis should at least satisfy the majority
of these criteria, and must meet the criterion of temporality which,
according to Rothman and Greenland (8), is the sine qua non-for
causality (5).
Multiple studies confirm that CU is approximately two times
more frequent among people with schizophrenia than in the gen-
eral population (9, 10). Furthermore, CU is considered a signifi-
cant risk factor for both suicide attempts and behavior in psychotic
samples (11). This raises the question of whether cannabis plays
an etiological role in the onset of schizophrenia, or whether peo-
ple with schizophrenia are prone to increased use of cannabis.
Studies of retrospective reports on CU typically show that approx-
imately one third of individuals commence CU prior to onset of
psychotic illness (12, 13). Retrospective studies are subject to recall
bias; thus prospective data is required to confirm temporal priority
(and thus causality) of CU. A number of systematic reviews have
focused on prospective studies only with longitudinal designs and
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these report pooled odds ratios varying between 1.41 and 2.34 (5,
14, 15). Henquet et al. (14), whose analysis arrived at a pooled odds
ratio of 2.1, noted that this result held regardless of whether studies
with narrow clinical outcome were included (OR: 2.4) or whether
those with broader outcomes were included (OR: 1.9). Interest-
ingly, Arseneault et al. (5) who arrived at a pooled odds ratio of
2.34, included a very narrow definition of clinical outcomes; while
Moore et al. (15), who arrived at a pooled odds ratio of 1.41 in
their systematic review, included a very broad definition of psy-
chotic outcomes. The impression therefore from these systematic
reviews is that narrow definitions of psychosis (i.e., limited to non-
affective psychosis/schizophrenia-spectrum) are associated with
slightly higher odds ratios of approximately 2.3–2.4; while broader
definitions are associated with slightly lower odds ratios of approx-
imately 1.4–1.9. Notably, all studies included in these three major
systematic reviews adjusted for a range of confounding factors. In
summary, these reviews suggest that CU is associated with roughly
a twofold increased risk of developing psychosis (specifically non-
affective, schizophrenia-spectrum disorders), thereby confirming
an association between exposure and outcome.
Temporal priority of CU was confirmed in at least two studies
which showed that CU during early adolescence increases the risk
for later non-affective psychosis outcome (4, 16). In the Dunedin
Study in New Zealand, a general population birth cohort of 1037
individuals were assessed at age 11 for psychotic symptoms, at ages
15 and 18 for self-reported CU, and at age 26 for schizophrenia
and schizophreniform disorder outcomes (4, 5). Thus, controlling
for psychotic symptoms at baseline, the authors were able to show
an association between CU at ages 15 and 18 and increased risk
for psychotic symptoms at age 26 years. Early CU (by age 15) was
associated with a threefold increased risk of schizophreniform dis-
order at age 26 years (thus confirming temporal priority); but was
not associated with later depressive outcomes (thereby indicating
specificity of outcome). The use of other drugs in adolescence did
not predict psychotic outcomes over and above the effect of CU
(indicating specificity of the exposure) (5). The Dutch NEME-
SIS study (10) as well as the Swedish conscript follow-up study
(17) both demonstrated a dose-response relationship between
increased CU and increased risk of later psychosis – in the NEME-
SIS study, the highest risk (OR: 6.8) was associated with the highest
level of CU.
In conclusion, there is good scientific evidence, emanating from
a number of key studies involving careful longitudinal designs, to
conclude that a causal relationship does exist between CU and
psychotic illness. Specifically, these studies suggest that this rela-
tionship exists in relation to non-affective schizophrenia-spectrum
disorders. These studies have demonstrated most of the key criteria
for establishing causality, namely: association; temporal prior-
ity; specificity; and strength (dose-response relationship). What
remains to be considered is the question of plausibility – is there a
plausible biological mechanism that could explain the etiological
role of cannabis in psychosis and schizophrenia?
THE NEUROBIOLOGICAL BASIS OF CANNABIS AS A CAUSE
OF PSYCHOSIS
In the early 1990s, the cannabinoid (CB) receptors were geneti-
cally determined – the distribution of CB1 was mapped in high
densities to the striatum, hippocampus, and cerebellum; and in
moderate to low densities to the amygdala, midbrain, and cerebral
cortex (18). CB1 are situated on presynaptic terminals that release
GABA, glutamate, serotonin, dopamine, and Ach; and interaction
between this receptor and its endogenous endocannabinoid lig-
ands (e.g., anandamide) results in limiting of neurotransmitter
release (19). Thus this system plays an important role in main-
taining and determining synaptic plasticity. Importantly, endo-
cannabinoid signaling is present during gestation and early infancy
and plays a critical role in neuronal proliferation,migration,axonal
guidance, positioning of cortical interneurons, and synaptogene-
sis (20). Experimental aberrations in endocannabinoid signaling
during critical periods result in significant disruptions in neurode-
velopment. While the role of endocannabinoid signaling during
adolescence has not been fully elucidated, one may reasonably
assume that the neurodevelopmental role of this system contin-
ues during adolescence when regions such as the hippocampus
and prefrontal cortex are still undergoing marked development
(18). Notably too, CB1 expression patterns increase dramatically
throughout the adolescent period in areas including the frontal
cortex, striatum, and hippocampus (21). Likewise, there appear to
be peaks in endocannabinoid levels during the adolescent period
(22, 23). Thus, as Malone et al. (18) conclude, “endocannabi-
noid signaling is an important determinant of maturation of the
adult brain. . . it seems quite likely that disruption of normative
endocannabinoid signaling during adolescence may have long-
standing consequences on adult brain function.” Animal models
show that early exposure to CB agonists result in a variety of mostly
cognitive deficits in adult animals, including working memory dys-
function, disruption in pre-pulse inhibition of startle (a measure
of sensory gating), a significant decrease in social behavior and
increased locomotor activity (24–26). In summary, these obser-
vations have led to the so-called “endocannabinoid hypothesis of
schizophrenia” (27).
Disruption of the CB system during development impacts on
several other neurotransmitter systems, notably the GABA and
dopamine systems. GABAergic neurons in the prefrontal cortex
are rich in CB1 receptors which, when activated, result in a decrease
in extracellular GABA release (28). It has been hypothesized that
repeated exposure to cannabis during adolescence may alter the
balance of GABAergic inhibitory inputs to pyramidal neurons
in the prefrontal cortex that could lead to impaired cognitive
function (29). Furthermore, CU leads to increased extracellular
dopamine; probably through the activation of CB1 receptors on
GABAergic interneurons, which in turn disinhibit dopaminergic
neurons (30). Kapur (31) has argued that psychosis results from
aberrant reward prediction and abnormal attribution of salience
caused by disordered dopamine transmission; while Laruelle (32)
postulated that the dopaminergic abnormalities associated with
schizophrenia are due to “dopamine sensitization” beginning in
adolescence. Dopamine sensitization has been suggested in rela-
tion to the links between early stress and trauma (e.g., childhood
sexual abuse) and the observed increased risk for schizophrenia
(33). Evidence supporting the role of dopamine sensitization in
CU, comes from a study by Houston et al. (34) where a signif-
icant interaction was found between early exposure to cannabis
and childhood sexual trauma on psychosis outcome. Importantly,
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in this study, no main effect was observed for either sexual trauma
or CU on psychosis outcome; suggesting that previous exposure to
stress sensitizes individuals, so that subsequent life stresses evoke
progressively greater responses over time (i.e., in this case there
is cross-sensitization between early stress and cannabis) (35). In
terms of dopamine sensitization, the individual eventually reaches
a lasting state of dopamine dysregulation (36, 37). Henquet et al.
(35) note that the dose-response relationship between CU and risk
for psychosis suggests a dopamine sensitization process.
THE BIOLOGICAL BASIS OF DIFFERENTIAL RISK FOR
PSYCHOSIS IN CANNABIS USERS
Cannabis is the most widely used drug in the world – millions
of people use it – however, only a small proportion of users
develop psychotic illness. This suggests that individual genetic fac-
tors must play a role in altering individual susceptibility to the
psychotic-inducing potential of cannabis; thus gene-environment
interactions are implied.
There are two ways to measure genetic liability to psychosis –
directly and indirectly (14). Indirect measurement involves the use
of individuals who are shown to exhibit liability to psychosis (mea-
sured using psychosis proneness scales) or are liable to psychosis
by virtue of being first degree relatives of psychotic probands.
Individuals measured as liable to psychosis are at greater risk of
developing cannabis-induced psychotic experiences during the
flow of everyday life (38); and their 3–5 year risk of developing
psychotic symptoms while using cannabis is 51% compared with
21% in those using cannabis who do not show psychosis liability
(39). A family study by McGuire et al. (40) found that patients who
developed acute psychosis after using cannabis were more likely to
have a positive family history of schizophrenia than those patients
who screened negative for CU.
Unlike indirect measures of genetic risk which rely on psy-
chosis liability, presumably of genetic origin, direct measures rely
on actual analysis of genes, their polymorphisms and their expres-
sion patterns. During the last 8 years, there has been considerable
interest in the catechol-O-methyltransferase (COMT) gene in rela-
tion to liability to psychosis and various environmental factors
including cannabis. TheCOMT gene is notable as a candidate gene
for psychosis since: it is located on chromosome 22q11, a region
already implicated in schizophrenia; a microdeletion of chromo-
some 22q11 is associated with velo-cardio-facial syndrome (which
has a high rate of psychosis); and finally, the COMT gene codes
for the enzyme catechol-O-methyltransferase which is involved in
the metabolism of dopamine at synapses (41). From the Dunedin
Study (described above), Caspi et al. (41) showed that a func-
tional polymorphism of the COMT gene moderates the effect of
adolescent CU on risk for adult psychosis. Homozygous carriers
of the COMT valine158 allele (i.e., Val/Val) were most likely to
exhibit psychotic symptoms and later develop schizophreniform
disorder if they had used cannabis during adolescence (RR: 10.9).
Heterozygous individuals with the valine/methionine (Val/Met)
genotype who had used cannabis during adolescence showed an
intermediate risk; while those homozygous for the methionine
allele (Met/Met) showed the lowest risk (RR: 1.1). It is impor-
tant to note that the authors emphasize the fact that this effect
was observed in those with adolescent-onset CU and not in those
with adult-onset CU. This is important for understanding the rel-
ative impact of cannabis on the developing versus the developed
brain in relation to its causal role in psychosis. Several studies
have subsequently partially replicated this result (42, 43), while
others have failed to replicate it (44). In a double-blind placebo
controlled trial in the Netherlands, Henquet et al. (42) showed
thatVal/Val carriers were more sensitive to memory and attention
impairments of delta-9-tetrahydrocannabinol (THC); although a
gene-environment interaction was not demonstrated as the geno-
type on its own was neither associated with cognitive impairments
nor associated with frequency of CU or being a patient.
Notably, COMT is predominantly expressed in the prefrontal
cortex (45), a region associated with executive functioning, work-
ing memory, and attentional deficits in schizophrenia. TheVal/Val
genotype is associated with increasedCOMT activity and Henquet
et al. (35) hypothesize that this may result in a combination of (a)
reduced dopamine neurotransmission in the prefrontal cortex,and
subsequently (b) increased levels of mesolimbic signaling which is
thought to result in increased risk of experiencing delusions and
hallucinations. Conversely, the Met/Met genotype is associated
with better prefrontally mediated executive function performance
than theMet/Val andVal/Val genotypes (46). Reasoning that since
COMT is especially important in the prefrontal cortex, and since
the prefrontal cortex is developing during puberty, Barnett et al.
(47) investigated the role of COMT genotypes on cognitive func-
tioning during puberty. They found that among boys who had
already entered puberty, those with the Met/Met genotype had an
average IQ 10 points higher than those with the Val/Val geno-
type. This relevant to our focus on psychosis and cannabis for two
reasons: first, it supports the neurodevelopmental model of schiz-
ophrenia (48) where genetic and environmental liabilities interact
with normal brain development to increase risk for the disor-
der (49); and secondly it provides a sound neurodevelopmental
framework within which the adolescent use of cannabis can be
understood as conferring increased risk for later psychosis.
CLINICAL PRESENTATION OF PSYCHOSIS IN CANNABIS
USERS – ARE THERE SPECIFIC FEATURES?
If cannabis does indeed play a causal role in psychotic illness and
there is differential risk for psychosis in cannabis users, then it
is pertinent to address the question of whether cannabis can be
distinguished clinically as an etiology for psychosis? The view of
the Indian Hemp Drug Commission over 100 years ago was that
there are no distinguishing clinical features of psychosis due to
CU (other than perhaps a shorter duration of the episode). Were
these early impressions correct? In answering this question it is
important to bear in mind the issue raised at the beginning of
this review, namely: one must differentiate between lifetime use
and recent/current use of cannabis as these may have quite dif-
ferent effects upon clinical presentation, course and outcome of
psychosis.
Duration of untreated psychosis (DUP) is the period between
the onset of the first psychotic symptoms and the initiation of
antipsychotic treatment. DUP has significance in that longer DUP
is associated with poorer response to treatment, more frequent
relapses and poorer long-term outcome of psychosis (50, 51). Con-
versely, early detection and intervention improves outcome to a
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considerable degree. The popular hypothesis linking long DUP
to the negative long-term consequences of psychosis relates to
proposed neurotoxicity; however, an analysis of the clinical and
neurobiological evidence for this hypothesis suggests that it is
in fact synaptic plasticity, and not neurotoxicity, that is one of
the most important mediating processes underlying this associa-
tion (52). The evidence-base supporting a link between DUP and
outcome is significant enough to have modified clinical practice.
There is therefore a good rationale for considering whether CU
impacts on DUP. A recent systematic review identified nine studies
with data on DUP and CU, and meta-analysis found no signifi-
cant difference in DUP between cannabis users and non-users (3).
However, the author noted that six of the nine studies reported
shorter DUP in cannabis users; and that “this association appears
to be true specifically for samples where CU is defined in terms
of current or recent use rather than lifetime use. . . Conversely. . .
lifetime use appeared to be associated with longer (or in one study
equivalent) DUP”(3). The author argues that this, along with other
evidence to be reviewed below, suggests there may be more than
one pathway to psychosis in relation to CU. In their first-episode
psychosis (FEP) study, Pelayo-Terán et al. (53) compared cannabis
users and non-users by COMT genotype and reported that those
with the Met/Met genotype showed a relatively short DUP, irre-
spective of CU status (53). Those with the Val/Val genotype who
were cannabis users also showed a short DUP, while non-cannabis
users with this genotype showed statistically longer DUP. Notably,
in this study, CU was defined in terms of recent use and – con-
sistent with Burns’ conclusions cited above – cannabis users all
showed shorter DUP, irrespective of their COMT genotype.
Early age of onset of psychosis is also associated with poorer
outcome in schizophrenia. Meta-analysis shows that age of onset
in cannabis users is 2.70 years earlier than in non-cannabis users;
and multiple meta-regression showed that a higher proportion of
cannabis users in the substance-using groups significantly con-
tributed to the heterogeneity in the effect size (54). The authors
argue that this finding lends support to the hypothesis that CU
plays a causal role in the development of psychosis in some indi-
viduals. In addition, it appears that a temporal direct relationship
may exist between the age at initiation of CU and age of onset
of psychotic illness; with a period of 7–8 years intervening (55).
In a sample of 997 individuals with psychosis, Stefanis et al. (55)
found a linear association between age of initiation of CU and
age of onset of psychosis; with those who had comorbid diagnoses
of schizophrenia-spectrum disorder and lifetime cannabis depen-
dence showing a slightly shorter period of premorbid cannabis
exposure (7 years). A similar association has also been shown
between earlier initiation of CU and early onset of high-risk
symptoms for psychosis (56), suggesting that CU from a young
age is associated with increased risk for a spectrum of psychotic
phenomena. Thus the evidence on cannabis and age of onset of
psychosis appears to support the hypothesis that early and pro-
longed use of cannabis is predictive of earlier onset, prognostically
poorer psychotic disorder in some individuals.
Interestingly, the COMT genotype shows an interaction with
CU in relation to age of onset (53). Pelayo-Terán and colleagues
found that among non-cannabis users, age of onset was signifi-
cantly later in those with the Met/Met genotype, compared with
those homozygous for the Val allele. However, in cannabis users,
there were no differences in age of onset between COMT geno-
types with all cannabis users having earlier age of onset. The
authors conclude that CU has the effect of reducing the delay
effect of the Met allele on onset of psychosis; thereby depriving
carriers of the relative protection conferred by this allele.
In terms of symptoms, most studies support the finding that
cannabis users with FEP tend to present with more prominent pos-
itive symptoms (hallucinations, delusions, and thought disorder)
and less prominent negative symptoms (apathy, social withdrawal,
amotivation, etc.) (57–61). Prominent positive symptoms at onset
are generally associated with a better course and outcome; while
prominent negative symptoms are associated with poor outcome.
Notably, Van Mastrigt et al. (57) defined CU in terms of recent
use and showed increased positive symptoms in cannabis users
at psychosis onset; while Compton et al. (60) reported a signifi-
cant relationship between daily CU just before onset of psychotic
symptoms, and an acute florid onset of psychosis. With respect
to negative symptoms, Burns et al. (58) defined CU in terms
of recent use and reported significantly lower negative symptom
scores at psychosis onset. Taken together, these findings suggest
that increased positive symptoms and reduced negative symptoms
at psychosis onset are likely to be associated with the acute effects
of recent/current CU specifically. This hypothesis is supported
by the findings of Baeza et al. (62) who measured positive and
negative symptoms at psychosis onset and again at 6 months in
32 cannabis-using and 78 non-cannabis-using children and ado-
lescents aged 9–17 years. CU was defined in terms of recent use
over the last month. At baseline (i.e., psychosis onset), cannabis
users had significantly greater positive symptoms and lower neg-
ative symptoms. However, at 6 months follow-up, cannabis users
had significantly lower positive and negative symptoms than non-
cannabis users; particularly those cannabis users who gave up
cannabis during the 6-month period. Some authors have argued
that lower negative symptoms in cannabis users is a function of
selection, whereby individuals with negative symptoms cannot
easily access cannabis due to the apathy, amotivation, and social
withdrawal that comprises the negative syndrome (59). However
this is unconvincing given the ease of access to cannabis in many
countries such as the Netherlands and South Africa (58).
COGNITION IN CANNABIS USERS WITH PSYCHOSIS
The cognitive effects of CU in individuals with psychosis is an
important and, as it turns out, fascinating topic. Long-term CU
in normal individuals without psychotic disorders is associated
with cognitive impairments, including residual memory and atten-
tional deficits following abstinence (63, 64). In addition, Yücel
et al. (64) have demonstrated structural brain abnormalities in
otherwise healthy long-term cannabis users. However, in individ-
uals with schizophrenia, long-term CU seems to have a different
effect on neurocognitive performance. Two meta-analyses show
that patients with schizophrenia who have a history of CU have
superior neurocognitive functioning than patients with schizo-
phrenia without a history of CU (65, 66). This somewhat unex-
pected finding appears to relate particularly to performance on
executive functioning, working memory, and visual functioning;
although meta-analysis of a global cognitive score also showed
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better performance in cannabis-using patients with schizophrenia
with an overall effect size of 0.35 (66). Further analysis demon-
strated that cannabis users performed significantly better (in terms
of the global cognitive score) only in the studies defining CU by
lifetime exposure (d = 0.55), but not in the studies using recent
use criteria. Furthermore, Jockers-Scherübl et al. (67) found that
earlier age of initiation of CU (before age 17 years) was asso-
ciated with even better neurocognitive performance in patients
with schizophrenia; while CU deteriorated cognitive performance
in healthy controls, especially in those who initiated use before
age 17 years. In a first-episode schizophrenia study, Yücel et al.
(66) confirmed the finding of better neurocognitive performance
in cannabis users; and replicated the finding that superior per-
formance is specifically associated with early initiation of CU.
Interestingly, more frequent CU has also been associated with bet-
ter cognitive performance, specifically in the domains of working
memory and attention (68).
Several explanations have been offered for this somewhat
counter-intuitive finding of superior cognitive functioning in
cannabis-using patients with schizophrenia. Some authors have
suggested that cannabis-using patients show superior social skills,
enabling them to access an illegal drug (69, 70). This however is
unconvincing and is not supported by data (71). As in the case
of negative symptoms (see discussion above), cannabis is readily
accessible in many countries such as the Netherlands and South
Africa; thus superior social skills are not necessary to obtain it.
It has also been suggested that cannabis may have a protective
influence on brain functioning, especially when consumed prior to
psychosis onset (67, 72). Jockers-Scherübl et al. (73, 74) found sig-
nificantly higher concentrations of neurotrophins [nerve growth
factor (NGF) and brain-derived neurotrophic factor (BDNF)]
in schizophrenia patients with previous CU, compared to non-
using schizophrenia patients. These authors suggest that “since
neurotrophins like NGF and BDNF are involved in the devel-
opment, plasticity, and maintenance of function of nerve cells,
their up-regulation in cannabis users who later develop schizo-
phrenia might correspond to an endogenous repair mechanism
for impaired nerve cells. Cannabis might induce this mecha-
nism, which in turn could help preserve cognitive function”
(67). Supporting this hypothesis is evidence from studies of both
non-clinical and other clinical (non-psychotic) populations that
cannabis may have neuroprotective and even neuroregenerative
properties (75–78); as well as the fact that CSF levels of the endoge-
nous CB, anandamide, are negatively correlated with psychotic
symptoms in acute untreated schizophrenia (79), suggesting an
endogenous compensatory adaptation within the CB system in
schizophrenia. The question of whether cannabis exerts positive
neuroprotective effects on individuals who later develop schizo-
phrenia, is likely to be controversial and highly complex and clearly
further research is indicated to resolve this issue.
Perhaps, the most convincing argument for better cognitive
functioning in cannabis-using schizophrenia patients is the fol-
lowing: those individuals who present with psychosis and a history
of long-term CU, early initiation of CU increased their risk for
developing psychosis, which otherwise may not have occurred in
the absence of CU (66, 68, 80). In other words, early CU may
induce psychosis onset in less cognitively vulnerable individuals.
On the other hand, non-cannabis users who develop psychosis
are likely to have greater genetic or developmental vulnerability
to psychosis; thus they manifest poorer cognitive performance at
psychosis onset. As Yücel et al. (66) point out, the evidence that
cannabis initiation before the age of 15 years is associated with
greater risk for subsequent psychosis (4, 5), supports this hypoth-
esis. It is possible that, in the absence of cannabis, these individuals
may have remained asymptomatic. Evidence that cannabis users
at first-episode have fewer neurological soft signs (minor physical
anomalies attributed neurodevelopmental factors) than non-users
supports the hypothesis that cannabis users have less neurodevel-
opmental impairment (81). The fact that more frequent use of
cannabis has also been associated with better cognitive perfor-
mance (68), further supports this hypothesis; as here one might
speculate that a greater magnitude of toxic insult is required to
induce psychosis in individuals who are particularly invulnerable
to psychosis.
Somewhat at odds with the hypothesis that cannabis-using
schizophrenia patients have better cognitive performance and less
neurodevelopmental impairment than non-users, is data suggest-
ing structural brain abnormalities in users, especially in areas rich
in CB1 receptors such as the cingulate and prefrontal cortices and
cerebellum (82). In addition, two studies show reduced cortical
thickness in users compared with non-users (83, 84). However,
many of these studies have important limitations including: study
populations are often individuals with established schizophrenia
[e.g., Habets et al. (84)] and findings in these patients cannot
differentiate between premorbid vulnerability markers and pro-
gressive changes during the course of the disease; and there is often
comorbid alcohol or other substance use which is likely to con-
found results. In order to clarify this issue, first-episode samples
must be studied, without other comorbid alcohol or substances.
In a systematic review of the effects of CU on brain structure in
schizophrenia, only four papers report on populations meeting
these criteria and three of these report data from the same lon-
gitudinal cohort (82). Firstly, in Utrecht, Netherlands, Cahn et
al. (85) reported from a cross-sectional FEP study no differences
in global brain and caudate nucleus volumes on MRI between
cannabis users and non-users. In the same group, Rais et al. (83,
86) reported no differences in ventricular size or cortical thick-
ness at baseline in cannabis-using, first-episode schizophrenia
patients; but at 5 year follow-up, those who used cannabis dur-
ing the scan interval showed increased lateral and third ventricle
volumes and loss of cortical thickness in the anterior cingulate
cortex (ACC) and dorsolateral prefrontal cortex (DLPFC). In a
different cross-sectional FEP study, Szeszko et al. (87) reported
gray matter deficits in the ACC in those with a comorbid diagno-
sis of cannabis dependence or abuse. However, in a recent study
of 54 first-episode schizophrenia patients, those with a lifetime
history of CU (n= 30) showed higher gray matter density in the
left frontal middle gyrus than those with no history of CU; and
this was positively associated with better cognitive performance on
the Continuous Performance Task (CPT), a measure of prefrontal
cortex integrity (88). Notably, impaired performance on the CPT
(in the domains of working memory, attention, and vigilance) is
regarded by some as a biological trait marker for schizophrenia
(89). These authors conclude that their results “provide further
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support for the hypothesis of a lower vulnerability for schizo-
phrenia in at least a subgroup of cannabis-using schizophrenia
patients compared to cannabis naïve patients” (88). Finally, a very
recent systematic review of MRI studies in schizophrenia compar-
ing cannabis users and non-users, reported inconclusive results,
stating: “while there is some evidence that chronic cannabis abuse
could alter brain morphology in schizophrenia in patients contin-
uing their cannabis consumption, there is no convincing evidence
that this alteration takes place before the onset of schizophrenia
when looking at first-episode patients” (90).
In concluding this section then, it seems the strongest evidence
supports the hypothesis that early CU may induce psychosis in less
vulnerable individuals who otherwise may have remained well.
DOES CANNABIS USE IMPACT ON COURSE AND OUTCOME
OF PSYCHOSIS?
While assumptions are commonly made by psychiatrists that CU
impacts negatively on course and outcome of psychosis, and the
seminal study of Linszen et al. (91) is often cited in support of
this view, Zammit et al. (92) conclude their systematic review
of the issue by stating: “We were surprised how little empiri-
cal evidence is currently available to support this view.” In their
review of 13 studies that met criteria, these authors note that few
studies of outcome adjust for baseline severity, and most make
no adjustment for alcohol or other potentially important con-
founders. It is thus only worth reviewing here the findings of
the three studies (93–95) that did adjust for baseline severity and
for alcohol and other substance use – since these are major con-
founders which undermine the validity of the results of studies
failing to include these adjustments. In Brisbane, a dose-response
association was demonstrated between CU (days per week) and
increased relapse, and in addition, increased psychotic symp-
toms predicted relapsed CU (93). This suggests a bidirectional
relationship between CU and psychotic symptoms – thus one
cannot assume that ongoing CU is causal of symptom relapse.
Increased relapse of symptoms in association with cannabis was
also reported from Melbourne (94) and Sydney (95), although it
is important to note that neither of these studies were in FEP pop-
ulations. There is also evidence that the greatest risk of relapse is
associated with ongoing CU during follow-up (96). While some
studies with less rigorous methodology have reported increases in
positive and/or negative symptoms with ongoing CU, the only one
of the three Australian studies cited above that reported increased
positive symptoms is the Sydney study (95); while none found
increased negative symptoms. The study of children and adoles-
cents with FEP by Baeza et al. (62) cited earlier in this review,
is notable in relation to symptoms at follow-up. Recent CU just
prior to onset was associated with increased positive symptoms
and lower negative symptoms. However, at 6 months follow-
up, cannabis users had significantly lower positive and negative
symptoms than non-cannabis users; particularly those cannabis
users who gave up cannabis during the 6-month period. Thus,
in conclusion, it seems Zammit et al. (92) are correct in their
assessment and that there really is not any substantial evidence
supporting assumptions made about poorer course and outcome
in psychosis in relation to premorbid CU. Ongoing CU however
appears to have a reciprocal impact on perpetuating psychosis into
a possibly progressive, relapsing, deteriorating schizophrenia-like
disorder.
PATHWAYS FROM CANNABIS TO PSYCHOSIS
Having reviewed multiple aspects of the relationship between CU
and psychosis, it is now possible to propose a model which involves
several pathways from cannabis to psychosis. Importantly, the
factors that are key to the various pathways include;
• Early initiation/lifetime use of cannabis versus recent cannabis
use.
• Underlying genetic vulnerability to psychosis/schizophrenia.
• Ongoing cannabis use after psychosis onset versus stopping
cannabis use.
Two major pathways from cannabis to psychosis are proposed.
Firstly, early initiation of CU during adolescence and lifetime use
in genetically vulnerable individuals, gives rise to neurodevelop-
mental changes that sensitize individuals to later psychosis – pos-
sibly through disruption of normal endocannabinoid, GABA and
dopaminergic systems (see Figure 1). These are individuals who
are genetically vulnerable, but in the absence of cannabis they may
have remained asymptomatic. The implication is that their degree
of genetic vulnerability is not as significant as that in individuals
who become psychotic in the absence of CU (see Figure 2). These
individuals (cannabis users) present at psychosis onset with mixed
prognostic features – early age of onset, long DUP, high positive
and low negative symptoms and relatively normal cognition and
brain structure on MRI. If CU ceases at first-episode, then a pos-
itive outcome with significant improvement may be anticipated.
However, if CU continues after psychosis onset, a poorer course
and outcome characterized by repeated relapse and neurocogni-
tive deterioration is likely. In this scenario, it appears that ongoing
CU and exacerbation of psychotic symptoms impact on each other
reciprocally, in a cycle of deterioration that is mirrors the underly-
ing progression of cognitive and structural brain impairment. In
such cases, the chronic deteriorating psychotic disorder is indistin-
guishable from schizophrenia – and in terms of current psychiatric
nosology should probably be considered as schizophrenia.
The long-term outcome of early-initiated/lifelong CU in indi-
viduals who are not genetically vulnerable to psychosis, is less clear
and certainly an area for future research. It is feasible that several
outcomes are possible, depending on individual genetic and devel-
opmental factors, frequency, volume, and duration of CU, as well
as the presence or absence of other risk factors for psychosis (such
as early trauma, abuse, and stress). It is reasonable to assume that
some individuals follow a course into psychosis as described above
for genetically vulnerable persons; others may experience fluctu-
ating psychotic-like symptoms that remain clinical insignificant;
while others may experience a completely asymptomatic course
long-term.
The other major pathway from cannabis to psychosis occurs
in individuals without a lifetime history of CU, but who begin
to use cannabis shortly before psychosis onset (see Figure 3).
Where acute psychosis is apparently “precipitated” by recent CU,
it is reasonable to assume such individuals are already geneti-
cally and developmentally vulnerable to psychosis. Thus, unlike
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FIGURE 1 | Pathway to psychosis in early-initiated, lifelong cannabis users.
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FIGURE 3 | Pathway to psychosis in recent use cannabis users.
early-initiated, lifetime cannabis users (who are vulnerable to psy-
chosis as a result of lifelong cannabis-induced neurodevelopmen-
tal dysregulation), these individuals are susceptible to psychosis for
genetic and developmental reasons alone. The acute “cannabis-
induced” psychosis is characterized by prognostically better fea-
tures including: later age of onset; shorter DUP; and prominent
positive and absent negative symptoms. In the acute phase, cogni-
tive deficits may be evident, but are transitory and reversible if CU
ceases, with a good outcome expected. Where CU continues after
psychosis onset, a poorer outcome might be expected – but this is
less clear and also an area meriting further research.
A large number of people use cannabis frequently without expe-
riencing any psychotic symptoms or disorder. Presumably, these
are individuals with low genetic and developmental vulnerability
to psychosis.
CONCLUSION AND FUTURE RESEARCH
In conclusion, the relationship between CU and psychosis is com-
plex and it is not possible to describe a single scenario that pertains
to all individuals whose CU contributes to subsequent psychosis.
In addition, variations in cannabis composition between indi-
viduals and over time are likely to contribute to heterogenous
courses and outcomes. Evidence showing that the cannabis prod-
uct cannabidiol (CBD) may protect against the psychosis-inducing
effects of THC (97) implies that consumption of cannabis with a
high THC:CBD ratio is more likely to be associated with psychotic
outcomes. It is clear that at least two pathways from cannabis to
psychosis exist. Early-initiated, lifelong CU in vulnerable individu-
als may lead to a psychotic illness virtually indistinguishable from
schizophrenia at onset. It appears that outcome however is dis-
similar to schizophrenia in those who cease to use cannabis after
onset. In those whose CU persists, a chronic deteriorating disorder
seems to follow – in these cases one may conclude that cannabis has
been played a causal role in schizophrenia. Recent use of cannabis
in vulnerable individuals, just prior to psychosis onset, is clini-
cally distinguishable from schizophrenia at first-episode. Ceasing
CU after the first-episode appears to have an excellent progno-
sis, with full recovery achievable in most cases. The long-term
consequences of continued CU however are not clear.
There is clearly a need for future research to clarify and con-
firm these differing pathways and complex associations between
CU and psychosis. Such research should be carefully designed to
take into account key factors that to date have often been blurred,
thereby confusing the research field. The ideal study would include
the following methods:
1. A first-episode psychosis population with narrow diagnostic
definitions of non-affective or schizophrenia-like psychosis.
2. A detailed history and description of CU, including: age at initi-
ation; frequency and extent of cannabis consumed; and a clear
description of patterns of recent use.
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3. History of other risk factors for psychosis (e.g., childhood
trauma).
4. Measures of vulnerability or proneness to schizophre-
nia and psychosis – these may be indirect (e.g.,
familial history) or direct (genetics; neuropsychological
endophenotypes).
5. A longitudinal study design with clear baseline and follow-
up measures of psychopathology, cognitive functioning, and
ongoing CU.
Such studies will move this field forward considerably and bring
us closer to answering the long-standing questions of how CU
impacts on the brain and how this leads some individuals into
psychotic illness and even schizophrenia. They will also clarify the
issue of outcome and prognosis for individuals with a cannabis
history who develop psychosis. Finally, elucidating the pathways
from cannabis to psychosis will contribute substantially to ongoing
efforts to understand the causes, development and natural history
of schizophrenia and its related disorders.
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